Audited Financial Results for the Quarter and Year ended 31.03.2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical reported a net loss of Rs. 1,757.17 lakhs for FY26, significantly higher than the loss of Rs. 1,029.83 lakhs in FY25. Revenue grew marginally by 3.4% to Rs. 11,298.19 lakhs. The company continues to operate at a loss with negative earnings per share of Rs. 4.75. Total equity has turned negative at Rs. 4,268.68 lakhs (negative net worth), indicating accumulated losses exceed share capital. Borrowings increased sharply to Rs. 10,956.68 lakhs from Rs. 6,193.24 lakhs previously. Operating cash flow was negative at Rs. 890.81 lakhs. The company also recognized an Expected Credit Loss provision of Rs. 52.86 lakhs on trade receivables. Virupaksha Organics Limited acquired 56.5% stake in June 2025, making it the holding company. The auditors issued an unmodified opinion.
The company is in significant financial distress with negative net worth and increasing losses. Shareholders face extreme risk as the company may struggle to meet debt obligations. The negative equity position and negative operating cash flow are serious red flags.